We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03645057
Recruitment Status : Completed
First Posted : August 24, 2018
Results First Posted : October 31, 2022
Last Update Posted : October 31, 2022
Sponsor:
Information provided by (Responsible Party):
Julie Ryan Wolf, University of Rochester

Brief Summary:
This is an open-label, randomized, cross-sectional study to monitor the effects of crisaborole and tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children (ages 2 to 15 years, inclusive) with ≤ moderate atopic dermatitis over a 12 week period of time. The goal of this study is to detect changes in PROs and caregiver burden during treatment for atopic dermatitis of moderate or less severity. The study design will allow us to correlate PROs and caregiver burden with treatment response and disease improvement in children.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Crisaborole Drug: Tacrolimus 0.03% Ointment Phase 3

Detailed Description:
Atopic dermatitis (AD) is a common, chronic skin disease affecting 20% of children and 10% of adults worldwide (1-3). Children with AD often develop the disease within the first five years of life, which is a critical time for physical and psychosocial development (4). AD impacts an individual's physical, mental, and social health. Anxiety, itch, sleep disturbance, and depression have been associated with low quality of life scores. Childhood AD also affects the emotional, financial, physical, and social well-being of parents or caregivers (4). Individuals caring for a child with AD report sleep deprivation, poor social support, and stress about parenting (1, 4). Utilizing patient-reported outcomes (PROs) in clinic can provide meaningful data to monitor disease activity and response to different interventions, with the ultimate goal to improve quality of life for the patient and their family members or caregivers. Additionally, PROs can help us better understand the burden of AD. It is still unclear which PROs are most relevant for atopic dermatitis. This study will evaluate the utility of several PROs to monitor response to two different topical ointments, crisaborole (Eucrisa™) and tacrolimus 0.03%, to better understand the impact of these two non-steroidal topical treatments on overall health of children with AD of moderate or less severity and their caregivers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is an open-label, randomized, cross-sectional study to monitor the effects of crisaborole and tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children (ages 2 to 15 years, inclusive) with ≤ moderate atopic dermatitis over a 12 week period of time.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS
Actual Study Start Date : February 20, 2019
Actual Primary Completion Date : August 1, 2021
Actual Study Completion Date : August 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Caregivers Eczema

Arm Intervention/treatment
Experimental: Crisaborole
The topical treatment will be applied to all affected areas twice daily for 12 weeks.
Drug: Crisaborole
This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
Other Name: Eucrisa

Active Comparator: Tacrolimus 0.03%
The topical treatment will be applied to all affected areas twice daily for 12 weeks.
Drug: Tacrolimus 0.03% Ointment
This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
Other Name: Protopic




Primary Outcome Measures :
  1. Mean Change in Children's PROMIS Pediatric Itch Short-Form [ Time Frame: baseline to 12 weeks ]
    This is a patient-reported outcome measure for Itch in pediatric patients that consists of 8 fixed items items, spanning four domains (general, activity, mood/sleep, and scratching behavior). Each item is scored on using 1 = No Itch, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very Severe. The range of the scale is 1 to 5 with higher numbers indicating worse outcome. A total score, representing overall itch-related quality of life, is scored by taking the average (i.e., divide by 8) of the sum of all 8 items. Therefore, total itch scores range between 1 and 5, with higher scores indicating worse impact of itch on quality of life. The measure was completed electronically on an iPad using REDCap.

  2. Mean Change in PROMIS Pain Interference-Children (Adaptive Test) [ Time Frame: baseline to 12 weeks ]
    This is a patient reported outcome measure for pain interference in pediatric patients. This is a computer adaptive test consisting of 4-12 questions related to how pain interferes with daily activities. The number of questions a patient answers depends on how he or she answers each question. The overall domain score ranges from 0 to100 with a score of 50 representing the average score for the general population. Higher scores indicate greater pain interference. A score above 55 is considered "clinically significant" for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This measure was completed electronically on an iPad using REDCap.


Secondary Outcome Measures :
  1. Mean Change in Children's Dermatology Life Quality Index [ Time Frame: baseline to 12 weeks ]
    This patient-reported outcome measure will be completed using an iPad. The 10-item questionnaire designed for use in parents of children (i.e., ages 4-17) to obtain information on children's quality of life. Each question relates to a component of quality of life: Symptoms/Feelings (items 1-2); Leisure (items 4-6); School (item 7); Relationships (items 3-8); Sleep (item 9), and Treatment (item 10). Children answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30). Higher the scores, the greater burden on quality of life. The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30.

  2. Mean Change in Children's Sleep Habits Questionnaire [ Time Frame: Baseline to 12 Weeks ]
    This patient-reported outcome measure was completed by the caregiver using an iPad. This is a validated 22 item questionnaire consisting of 4 subscales: Bedtime, Sleep Behavior, Waking During the Night, and Morning Wake Up. The patient/parent will answer each item choosing from: "Always" if something occurs every night; "Usually" if it occurs 5 or 6 times a week; "Sometimes" if it occurs 2 to 4 times a week; "Rarely" if it occurs once a week; and "Never" if it occurs less than once a week. Each question is scored on a 3-point scale as 1 = Usually and Always (5-7 times/week); 2 = Sometimes" (2-4 times/week); or 3 = Rarely and Never (0-1 time/week). The scores are combined from each subscale to generate a Total Sleep Disturbance Score, which can range from 22 (minimum) to 66 (maximum). The higher the score, the greater the sleep disturbance. A Total Sleep Disturbances score over 28 represent clinically significant sleep disturbance.

  3. Mean Change in PROMIS Anxiety-children (Adaptive Test) [ Time Frame: baseline to 12 weeks ]
    This patient-reported outcome measure will be completed by the child patient electronically on an iPad using computer adaptive test (CAT). The CAT consists of 4-12 questions on feelings related to anxiety. The number of questions a patient answers depends on how he or she answers each question. The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population. Higher scores indicate greater anxiety. A score above 55 is considered "clinically significant" for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This PRO was completed electronically on an iPad using REDCap.

  4. Mean Change in PROMIS Depressive Symptoms-Pediatric (Adaptive Test) [ Time Frame: baseline to 12 weeks ]
    This patient-reported outcome measure s will be completed by the child patient electronically on an iPad using computer adaptive test (CAT). The CAT consists of 4-12 questions on feelings related to depressive symptoms. The number of questions a patient answers depends on how he or she answers each question. The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population. Higher scores indicate greater depressive symptoms. A score above 55 is considered "clinically significant" for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This PRO was completed electronically on an iPad using REDCap.

  5. Mean Change in Children's Eczema Area & Severity Index (EASI) [ Time Frame: baseline to 12 weeks ]
    Clinician rated the severity of atopic dermatitis using the EASI. The EASI is a tool used to measure the extent (area) and severity of AD. It does not include a grade for dryness or scaling and includes only inflamed areas. The area score is a 7-point scale representing the percentage of skin affected by AD for each body region. The severity score is recorded for each of the four regions of the body and is the sum of the intensity scores for four signs. The four signs include redness, thickness, scratching, and lichenification. The intensity scores are performed using a 4-pont scale. The final EASI score is the sum of the total scores for each region. Add up the total scores for each region to determine the final EASI score. The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores represent worse AD severity.


Other Outcome Measures:
  1. Mean Change in Caregiver Burden Inventory [ Time Frame: baseline to 12 weeks ]
    The CBI is a 24-item, five-subscale Caregiver Burden Inventory (CBI) and demonstrates its use as a diagnostic tool for caregiver burden. The five subscales include: Time Dependency, Development, Physical Health, Emotional Health, and Social Relationships. Each subscale contains 4-5 items which are statements of feelings. Caregivers use a 5-point scale, anchored by "0" = "Never" and "4" = "Nearly Always", to show how often the statement describes his/her feelings. Overall scores can range from 0 (minimum) to 96 (maximum), where a score near or above 36 indicates significant burden. Higher scores indicate greater caregiver burden (i.e., worse outcome). All subscales have a maximum score of 20, except Physical Health which has a maximum score of 16. Subscale scores and item scores help identify the underlying cause of caregiver burden. This measure will be completed electronically on an iPad using REDCap.

  2. Mean Change in Family Dermatology Life Quality Index [ Time Frame: baseline to 12 weeks ]
    The FDLQI is a 10-item questionnaire designed for adult family members of a patient with a skin disease. It measures the impact of the patient's skin disease on the family member's quality of life. The caregiver will answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30). Higher scores indicate worse quality of life. The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30. This measure will be completed electronically on an iPad using REDCap.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Pediatric Subjects:

  1. Male and female subjects of inclusive ages of 2 to 15 years (inclusive) at screening visit.
  2. Diagnosis of ≤moderate atopic dermatitis or eczema (ISGA 2 or 3 and ≥3% BSA, excluding scalp).
  3. If subject is taking or prescribed antihistamines, subject must be on stable dose of antihistamines.
  4. If subject is taking or prescribed topical steroids, subject must be on stable dose of topical steroids.
  5. If taking a systemic anti-inflammatory medication for atopic dermatitis or other condition, subject must be on stable dose of the systemic anti-inflammatory medication for six weeks prior to enrollment.
  6. If subject is currently taking or prescribed tacrolimus or crisaborole, or other steroid-sparring medication, subject must agree to two week (i.e., 14 days) washout period prior to randomization and Baseline Assessment for study.
  7. Caregiver (i.e., adult parent or guardian) must agree to participate in the study with the patient.

e) Subject must be able to read and speak English. f) Subject ages ≥8 years, is able to give assent.

Caregiver Subjects:

  1. Subject must be at least 18 years old and the parent or guardian of the eligible pediatric subject.
  2. Subject must be able to read and speak English.
  3. Subject must be able to give informed consent.

Exclusion Criteria:

  1. Pediatric subjects <2 years old or >15 years old are not eligible for participation in this study.
  2. Pediatric subjects with a diagnosis with another skin disease (i.e., not atopic dermatitis or eczema) are excluded to prevent confounding of results.
  3. Pediatric subjects currently on systemic anti-inflammatory therapy for atopic dermatitis or other indication are excluded.
  4. Caregiver subject <18 years old are excluded.
  5. Pediatric subject participation without caregiver participation is not allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03645057


Locations
Layout table for location information
United States, New York
University of Rochester Dermatology
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Investigators
Layout table for investigator information
Principal Investigator: Julie R Wolf, PhD, MPH University of Rochester
  Study Documents (Full-Text)

Documents provided by Julie Ryan Wolf, University of Rochester:
Informed Consent Form  [PDF] January 25, 2021

Layout table for additonal information
Responsible Party: Julie Ryan Wolf, Associate Professor of Dermatology & Radiation Oncology, University of Rochester
ClinicalTrials.gov Identifier: NCT03645057    
Other Study ID Numbers: RSRB73062
First Posted: August 24, 2018    Key Record Dates
Results First Posted: October 31, 2022
Last Update Posted: October 31, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Caregiver Burden
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Stress, Psychological
Behavioral Symptoms
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action